The results indicated that SELENOF KO impaired glucose metabolism in young mice characterized by hyperglycemia, serum insulin reduction, impaired glucose tolerance, decreased insulin sensitivity, decreased glucose catabolism and glycogen accumulation, increased gluconeogenesis and impaired AKT signaling pathway. This evidence concerns the gene AKT1 and Hyperglycemia.